Soler-Pérez María Araceli, Serrano-Córcoles Maria Del Carmen, Ferrer-Márquez Manuel, López-González María Del Mar, Pérez-Sáez Miguel Ángel, García-Torrecillas Juan Manuel
Medicina Familiar y Comunitaria, Distrito Sanitario Atención Primaria Almería, Grupo de Trabajo de Aparato Locomotor de la SAMFYC, UGC Nijar, Centro de salud Campohermoso, Níjar, Almería, España.
Medicina Familiar y Comunitaria, Grupo de Urgencias de la SAMFYC, Urgencias Hospitalarias, Hospital Universitario Torrecárdenas, Almería, España; Medicina Familiar y Comunitaria, Servicio de Urgencias, Hospital Universitario Torrecárdenas, Almería. Instituto de Investigación Biosanitaria ibs.Granada, Granada, CIBER de Epidemiología y Salud Pública (CIEBERESP), Madrid, España.
Aten Primaria. 2021 Aug-Sep;53(7):102051. doi: 10.1016/j.aprim.2021.102051. Epub 2021 Apr 22.
To evaluate the clinical response at 24weeks after injection, measured as pain relief and functional recovery, in painful shoulder syndrome (PSS) in primary care (PC).
Longitudinal case series with injection treatment in the scapulohumeral joint, describing functionality and pain evolution before and at 24weeks post injection.
Non-urban primary care centres.
Patients with osteoarticular shoulder pathology susceptible to injection, failure of pharmacological treatment and rating on the visual analogue scale (VAS) ≥4 or constant score (CS) ≤70.
Intra-articular injection of corticosteroid and local anaesthetic into the scapulohumeral joint, describing its evolution at 1, 4, 12 and 24weeks post injection.
Infiltration response according to EVA before and after, CS before and after, number of infiltrations, side effects, temporary inability to work (TIL).
Sixty-six patients receiving injection, mean age 51.1years (SD 14.7), 57.6% were women and 63.3% were injection in the right shoulder. A 22.7% required TIL and were discharged with a median of 14days (range 7-56days). They required an injection (80.3%) and the most frequent injection pathology was rotator cuff tendinitis (90.9%). They suffered mild side effects (9.4%). We found a decrease in pain from severe to mild and a functional improvement from poor to good. The variables: being retired (OR: 37.82, P=.001) and having an EVA score prior to injection >8 (OR: 15.67, P=.055, almost significant) were associated with poor response.
Intra-articular administration of corticosteroids in PSS reduces pain and provides functional improvement after the first week after injection, and is maintained in the long term. This allows a quick recovery to work after an injection at two weeks reducing recovery time by 50%, with few side effects.
评估在基层医疗中，注射后24周时疼痛性肩部综合征（PSS）的临床反应，以疼痛缓解和功能恢复来衡量。
对肩胛肱关节进行注射治疗的纵向病例系列研究，描述注射前及注射后24周的功能和疼痛演变情况。
非城市基层医疗中心。
患有肩胛骨关节病变且适合注射治疗、药物治疗无效、视觉模拟量表（VAS）评分≥4或恒定评分（CS）≤70的患者。
向肩胛肱关节内注射皮质类固醇和局部麻醉剂，并描述注射后1周、4周、12周和24周的情况。
注射前后的EVA浸润反应、注射前后的CS、浸润次数、副作用、暂时无法工作（TIL）情况。
66例接受注射的患者，平均年龄51.1岁（标准差14.7），57.6%为女性，63.3%在右肩注射。22.7%的患者需要暂时无法工作，出院时中位时间为14天（范围7 - 56天）。他们需要再次注射（80.3%），最常见的注射病变是肩袖肌腱炎（90.9%）。他们出现轻度副作用（9.4%）。我们发现疼痛从重度减轻到轻度，功能从差改善到良好。变量：退休（比值比：37.82，P = 0.001）和注射前EVA评分>8（比值比：15.67，P = 0.055，接近显著）与反应不佳相关。
在PSS中关节内注射皮质类固醇可减轻疼痛，并在注射后第一周后实现功能改善，且长期维持。这使得注射后两周能快速恢复工作，恢复时间减少50%，副作用少。
